亞盛醫藥-B：與阿斯利康血液研發卓越中心 Acerta 製藥達成臨床合作
uSMART友信智投6月22日消息，亞盛醫藥-B發佈《自願性公告》宣佈，公司與阿斯利康(LSE/STO/NYSE: AZN)血液研發卓越中心Acerta製藥已達成一項臨床研究合作。基於合作的條款，亞盛醫藥將支持其BCL-2選擇性抑制劑APG-2575與Acerta製藥的布魯頓酪氨酸蛋白激酶(BTK)抑制劑CALQUENCE® (acalabrutinib)的聯合治療展開臨床研究，以評估該聯合用藥在復發難治慢性淋巴細胞白血病(CLL) ╱小淋巴細胞淋巴瘤(SLL)患者中的臨床效果及安全性。
該項研究為全球多中心、開放性Ib/II期劑量遞增及劑量擴展探索研究，旨在評估APG-2575單藥或聯合CALQUENCE®治療復發難治CLL/SLL患者的安全性、耐受性及抗癌活性。該試驗目前已經在美國開展並完成首例患者給藥，並擬擴展至歐洲及澳大利亞。
CLL/SLL是一種成熟B淋巴細胞克隆增殖性腫瘤，是歐美最常見的成人白血病，約占所有白血病新發病例的30%。儘管一線方案明顯提高初治反應率，很多CLL患者需長期治療以維持該反應率，一旦復發往往預後極差。而近期有關CLL的研究發現，BTK抑制劑聯合另一個BCL-2抑制劑能加深反應率，甚至縮短治療週期，令患者達致臨床治癒並因此停止治療。1, 2APG-2575是亞盛醫藥在研的新型口服BCL-2選擇性抑制劑，通過選擇性抑制BCL-2來恢復腫瘤細胞的程式性死亡機制，擬用於治療多種血液惡性腫瘤。自2020年3月以來，公司就APG-2575獲得中國、美國多項Ib/II期臨床試驗許可。
圖片來源：披露易
股價自6月12日起反彈57.12%
亞盛醫藥-B於2019年10月28日登陸港交所，是港股首個“原創小分子新藥”企業，不過，股價首日高開低走，此後股價更是陰跌下行，最低曾觸及19.8港元，較發行定價(34.2港元)跌去42.1%，今年6月12日起，股價開始連日反攻趨勢，累計升幅57.12%，6月12日、15日、16日、17日、18日分別上升：16.95%、11.3%、7.42%、2.42%、11.12%。
圖片來源：uSMART友信智投
此外，近期亞盛醫藥的藥物研發進展捷報頻傳。
6月17日，亞盛醫藥宣佈，公司在研1類新藥IAP抑制劑APG-1387聯合恩替卡韋治療慢性乙型肝炎(CHB)的II期臨床研究已經在中國完成首例患者給藥。
6月18日，亞盛醫藥宣佈，公司已向國家藥監局新藥審評中心(CDE)提交HQP1351的新藥上市申請，用於治療伴有T315I突變的慢性髓性白血病(CML)慢性期和加速期患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
